Oral Sodium Clodronate for Nonmetastatic Prostate Cancer--Results of a Randomized Double-Blind Placebo-Controlled Trial: Medical Research Council PR04 (ISRCTN61384873)
| Autor: | Mahesh K. B. Parmar, Malcolm David Mason, Robert Huddart, Mark Stott, Nicholas D. James, M. Sokal, Anne C. R. Robinson, Matthew R. Sydes, Ruth E Langley, David P. Dearnaley, John Glaholm |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty medicine.medical_treatment Placebo-controlled study Administration Oral Antineoplastic Agents Kaplan-Meier Estimate Placebo Gastroenterology Prostate cancer Breast cancer Double-Blind Method Internal medicine medicine Humans Aged Bone Density Conservation Agents Radiotherapy business.industry Prostatic Neoplasms Bone metastasis Middle Aged Bisphosphonate medicine.disease Combined Modality Therapy Surgery Zoledronic acid Oncology Disease Progression Clodronic acid Clodronic Acid business medicine.drug |
| Zdroj: | JNCI Journal of the National Cancer Institute. 99:765-776 |
| ISSN: | 1460-2105 0027-8874 |
| DOI: | 10.1093/jnci/djk178 |
| Popis: | BACKGROUND: The most frequent site of metastases from prostate cancer is bone. Adjuvant bisphosphonate treatment improves outcomes of patients with bone metastasis-negative breast cancer, but the effects of bisphosphonates on bone metastases in prostate cancer are not known. METHODS: We performed a randomized double-blind placebo-controlled trial to determine whether a first-generation bisphosphonate could improve symptomatic bone metastasis-free survival (time to symptomatic bone metastases or death from prostate cancer) in men with nonmetastatic prostate cancer who were at high risk of developing bone metastases. Between June 1, 1994, and December 31, 1997, 508 men from 26 UK sites and one New Zealand site who were within 3 years of initial prostate cancer diagnosis with no evidence of metastases from current bone scanning were randomly assigned to daily oral sodium clodronate (2080 mg/day, n = 254) or placebo (n = 254) for a maximum of 5 years. Estimates of outcome risks were compared using Kaplan-Meier analyses. RESULTS: The groups allocated to each treatment were well balanced. After a median follow-up of nearly 10 years, no evidence of benefit to the clodronate group was observed in terms of bone metastases-free survival (clodronate versus placebo, 80 events versus 68 events; hazard ratio [HR] = 1.22; 95% confidence interval [CI] = 0.88 to 1.68) or overall survival (clodronate versus placebo, 130 deaths versus 127 deaths; HR = 1.02; 95% CI = 0.80 to 1.30). Adverse events, notably gastrointestinal problems and increased lactate dehydrogenase levels, were more frequent in the clodronate group than in the placebo group; otherwise, clodronate was well tolerated. Modification of trial drug dose was more frequent in the clodronate group than the placebo group (HR = 1.63, 95% CI = 1.21 to 2.19). CONCLUSION: Adjuvant sodium clodronate does not modify the natural history of nonmetastatic prostate cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|